Understanding bacterial growth mechanisms can potentially help uncover novel drug targets that are crucial for maintaining cellular viability, particularly for bacterial pathogens. In this important ...

Integral Molecular, a leading biotechnology company in Philadelphia, is honored to announce its recognition as an Employer of Choice by the City of Philadelphia's Department of Commerce, Office of ...

Like all cancers, bladder cancer develops when abnormal cells start to multiply out of control. But what if we could put a ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the licensing of fully human antibodies from Biocytogen (HKEX: 02315), a global biotech company dedicated ...

This is a useful study that adds new data to how different DAG pools influence cellular signaling, and dissects how the enzyme Dip2 modulates the minor lipid signaling DAG pool, which is distinct from ...

"We understand that spending and investment in drug discovery technologies-especially capital equipment ... DNA-encoded libraries (DELs), kinases, membrane proteins, and ligandability. The Ultra also ...

aHKU-Pasteur Research Pole, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China bWorld Health Organization Collaborating Centre for Infectious Disease ...

Lipid anchors on nerve cell membranes stabilize prion protein folding, inhibiting aggregation. Membrane-anchored proteins clump only when exposed to pre-formed protein aggregates, simulating ...

A research team has now used new in vitro and cell culture models to show that a lipid anchor on the outer membrane of nerve cells inhibits the aggregation of the prion protein. Researchers have ...

A surface protein on malaria sporozoites targeted by vaccines and antibodies. Its central repeat region is included in existing malaria vaccines. Discovering new targets on the sporozoite surface The ...

2 Invenra has launched its Rapid Antibody Discovery Service, designed to simplify and de-risk the preclinical development of bispecific antibodies while reducing costs and enhancing downstream ...